All In Biotech

Drug Trial Radar · NCT05721300

Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer

Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 2,215 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,215

Planned (sponsor's estimate)

Start

Feb 10, 2023

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Zhongshan Hospital (Xiamen), Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 35 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test the outcomes of HBsAg(+) patients in the treatments of NAs vs NAs plus IFN . The main questions it aims to answer are: 1. Clinical effect analysis of nucleoside analogs (NAs) group a group and NAs plus interferon group after 48 weeks of treatment; 2. Repetitive effect and time effect of different drug treatment at different follow-up time points; 3. To evaluate the difference of therapeutic effect of NAs or NAs combined with interferon; 4. Follow up and compare the incidence of early liver cancer in each group. Participants will be asked to receive NAs or NAs combined with interferon treatments, and Regular blood sampling and color ultrasound examination. Researchers will compare control group to see if occurrence of liver cancer.

Conditions

  • Hepatocellular Carcinoma
  • Chronic Hepatitis B

Interventions

  • NAs("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") combined with interferon treatmentsDrug

    NAs("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") combine with interferon treatments for 48 weeks, and then continue with NAs treatment("Entecavir"or"Tenofovir"or"Tenofovir alafenamide")

  • NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") treatmentsDrug

    patients receive NAs("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") treatment at least 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of early liver cancerTime frame: 1-3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Boheng Zhang

    Xiamen, Fujian, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.